Kambo therapy

What kambo is (and isn’t)

Kambo is the defensive skin secretion of the Amazonian giant monkey frog, Phyllomedusa bicolor. In traditional Matsés, Katukina, and other Pano/Arawakan practice, the secretion is collected from frogs harvested live and released, dried on wooden sticks, and applied to small burn points created on the upper arm, shoulder, or leg. Effects begin within a minute and last ~15–30 minutes.

Kambo is not a psychedelic, despite frequent marketing that groups it with psilocybin, ayahuasca, or 5-MeO-DMT. Its active peptides do not cross the blood-brain barrier in the same way as small-molecule psychedelics, and users do not typically experience meaningful alteration of consciousness — only intense physical effects. The frog peptides do interact with opioid receptors (dermorphin is a potent µ-opioid agonist, deltorphins act at δ-opioid receptors), producing transient analgesic and mood effects in some users, but nothing like the qualitative experience of a psychedelic.

The peptide pharmacology — and why it goes wrong

The scientific interest in P. bicolor skin peptides is legitimate; these compounds are studied for drug discovery. The problem is that the raw ritual preparation delivers a cocktail of peptides in uncontrolled proportions, and several of them have effects that combine badly:¹³

The pathway to harm most often documented in the clinical literature: vasoactive peptides disturb water and sodium handling via the hypothalamic-pituitary axis (SIADH), at the same time the ritual protocol tells the participant to drink several liters of water. The participant develops acute dilutional hyponatremia, brain water follows the osmotic gradient, cerebral edema develops, and in severe cases that progresses to herniation.

Documented adverse events

The 2022 systematic literature review by Pepe et al. documented additional associated pathologies — acute renal failure, dermatomyositis, esophageal rupture from severe vomiting, toxic hepatitis, psychosis, acute heart failure leading to death — and proposed a treatment algorithm for emergency clinicians encountering suspected kambo intoxication.³

The Soul Quest case

The most widely reported US fatality involved kambo indirectly. In 2018 a 22-year-old man died at Soul Quest (Florida) after a retreat combining ayahuasca with kambo. His death was attributed to hyponatremia — the same mechanism documented in the published case reports. In May 2024 a Florida jury awarded the family $15 million; Soul Quest filed for bankruptcy and closed in August 2024. The legal record is relevant both to ayahuasca retreat safety and to kambo specifically, and is the single best-documented US case of why stacking these practices in the same ceremony is dangerous.

Typical expected effects

In the majority of sessions at modest doses with proper screening, kambo produces:

• Facial flushing within 30–60 seconds.
• Tachycardia and blood-pressure swings (up, then down).
• Nausea and intense vomiting within 2–5 minutes.
• Sometimes diarrhea.
• Resolution of the acute effects in 15–30 minutes.
• Transient post-session euphoria/analgesia lasting hours.

Even in uneventful sessions the hemodynamic load is real; this is not a benign intervention.

Contraindications & screening

A responsible practitioner will screen against (at minimum):

• Any cardiac disease, arrhythmia, or uncontrolled hypertension.
• Severe renal or hepatic disease.
• Seizure disorder.
• Pregnancy or breastfeeding.
• Eating disorders, severe dehydration, or recent GI bleeding.
• Current SSRI/SNRI/MAOI use (particularly if also considering ayahuasca or other serotonergic medicine in the same retreat).
• Active or recently active psychotic illness.
• Mental health conditions for which vomiting is contraindicated.
• Same-day use of any other psychoactive substance, particularly other opioids.

Legal status

Kambo peptides are not federally scheduled in the United States. There is no FDA approval for any therapeutic use, and no recognized medical specialty body endorses it. Practitioners in the US are not regulated by any licensing framework comparable to medicine or nursing; the International Association of Kambo Practitioners (IAKP) is the largest self-governing body, but its certifications are not medical credentials and do not carry malpractice accountability.

A handful of state and local actions have banned or restricted kambo following adverse events; checking current state law is worthwhile before engaging a practitioner.

Clinical and research status

There are no Phase 2 or Phase 3 clinical trials for kambo in any indication. Pharmaceutical interest in isolated Phyllomedusa peptides (particularly dermorphin analogs for pain) is legitimate and ongoing, but that research is separated from ritual kambo use. Claims that kambo treats chronic pain, cancer, Lyme disease, depression, or addiction are not supported by controlled clinical data.

Bottom line

1. Kambo is not a psychedelic. Treat it as a pharmacologically active, medically unregulated intervention with documented fatalities.
2. The most dangerous configuration is kambo combined with ayahuasca or other serotonergic medicines, plus high water intake. This is the pattern in the best-documented US fatality.
3. Screening matters more than shamanic lineage. Ask what the practitioner does for people who develop headache, confusion, or seizures during a session. If the answer is not medically literate, walk away.
4. Before considering a kambo session, the ayahuasca guide and the integration therapy guide provide important adjacent context, particularly if you are considering a multi-modality retreat.